Gross margin of more than 90%, impact on the market value of hundreds of billions of ... This year more than 40 pharmaceutical companies "stacked" listed!

On December 17th, Chengdu Bett Pharmaceuticals' application for listing (initial public offering) was approved, and on December 16th, Yuekang Pharmaceutical's new share purchase entered the payment stage.
So far this year, more than 40 pharmaceutical companies have landed on the A-share, of which, Kanghua Bio into the most profitable new pharmaceutical shares, one sign up to earn more than 250,000 yuan;
This year more than 40 pharmaceutical companies landed A-shares, 60% of the "beach" section of the A-share listed pharmaceutical companies this year, the total market value of the first three quarters of the performance, this year's rise and fall as of December 18, the close of a sign to earn more than 250,000! Kanghua Bio into the most profitable pharmaceutical new shares June 16, Kanghua Bio officially landed on the GEM, a sign-off to earn more than 250,000, up more than 700% to become this year's most profitable pharmaceutical new shares.
data show that the company is a comprehensive research, development, operation of integrated vaccine production enterprises, at the same time for the current domestic first listed seller of human double cytocytosis vaccine production enterprises.
main business products include freeze-dried human rabies vaccine (human secondary cells) and ACYW135 group meningococcal polysaccharide vaccine.
the first three quarters of this year, Kanghua Bio's revenue was RMB825 million, up 180.37 percent year-on-year, and net profit was RMB344 million, up 288.47 percent year-on-year.
expected full-year net profit of RMB390 million to RMB425 million, up 108.91% to 127.65 percent year-on-year.
For performance growth, Kanghua Bio said, on the one hand, by the first half of 2019 workshop technical changes, sales in 2019 is less, in 2020 the company's products freeze-dried human rabies vaccine (human double body cells) due to market demand and other factors, product sales increased;
13 one-word boards into the pharmaceutical stock TOP20! Insulin tap again take heavy products on June 29, GanLi Pharmaceuticals officially landed on the Shanghai Stock Exchange, with 13 one-word board into the pharmaceutical stock TOP20, the market value once stood on the scale of hundreds of billions, as of December 18, the market value fell back to nearly 70 billion yuan.
data show that the company is mainly engaged in recombinant insulin similars raw materials and injections research and development, production and sales.
main products include recombinant insulin glyceride injection (commodity name: Changxiuyu), recombinant lai insulin injection (commodity name: rapid sci-flu), refined protein zinc recombinant insulin mixture injection (25R). In recent years, sales of the end-chemical insulin and similar drugs in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) have risen steadily, reaching a new high of nearly 25 billion yuan in 2019, up 14.62 percent year-on-year in the first half of this year, according to
meters of intranet data.
from the factory structure, multinational pharmaceutical companies have been leading the way, No. 1 and Nord, Sanofi, Lilly three combined market share of more than 70%.
it is worth noting that in recent years, with the continued strength of domestic pharmaceutical companies such as Ganli Pharmaceuticals, Tonghua Dongbao and Federal Pharmaceuticals, No. 1 and Nord's market share has fallen from 50% in 2017 to 47% in the first half of this year.
, Gan Li Pharmaceutical's men's winter insulin 30 injection was approved, won the first in China, this is after taking the door winter insulin injection in May this year, the first after another heavy product.
99.96%！ Science and technology plate pharmaceutical enterprises into a "gross margin of one brother" January 23, Ze-Jiang pharmaceutical landing branch of the board.
, the company is an innovative, driven chemistry and bio-new pharmaceutical development and manufacturing company focused on the treatment of tumors, bleeding and blood diseases, liver and bile diseases and immuno-inflammatory diseases.
the first three quarters of this year, Ze-Yuan Pharmaceuticals reported revenue of 27.98 million yuan, net profit loss of 228 million yuan, up 42.68 percent year-on-year, and gross margin of 99.96 percent.
expects the company to continue to lose money due to the fact that it has no drugs on the market for the full year, and that its current revenue is only occasional revenue from licensing products and a small amount of technical services, with a loss of 462 million yuan last year.
Recently, Ze-Yuan Pharmaceuticals issued a notice that Shanxi Province drug equipment centralized bidding procurement network and Sichuan pharmaceutical procurement supervision network issued a notice on the fourth batch of national organizations centralized procurement of drug varieties related procurement data, Sorafeini oral regular release Dosage forms (specification 0.2g) (referred to as solafinib) are included in the scope of centralized procurement of varieties, the product is one of the products of zealg pharmaceutical products toluene sulfonate donafinib tablets (referred to as Donaphinib).
Said Pharmaceuticals said that while the company is in the process of listing a different product, Donovany and Sorapinie, and the clinical efficacy and safety are superior to Sorafeini, but considering that Soravini is a competition for Donovani One of them, as well as Soraphini's entry into this centralized range of sourcing varieties, may lead to a decline in the market space for Donovany's first-line targeted drugs for advanced liver cancer, so there is a risk of a decline in market space and pricing after Donovany's listing.
Concino returned to the market value of 100 billion, Wantay Bio launched an impact on Concino: August 13 officially landed on the board, the same day the market value exceeded the 100 billion mark, and then fell back, as of the December 18 close, back to the ranks of 100 billion market value.
, Consino is an innovative vaccine company dedicated to the development, production and sale of vaccines that meet Chinese and international standards.
has promoted the development of a range of innovative vaccines, including 16 innovative vaccine products for 13 adaptations such as Ebola virus disease, meningitis, new coronavirus (COVID-19), white break, pneumonia, tuberculosis, shingles, etc.
net profit for the first three quarters of this year was 176 million yuan, and for the full-year results, Mr. Consino said it expected to continue to lose money because the company was still in the product development and development phase and had no products on the market.
: April 29 landed on the Shanghai Stock Exchange, 26 consecutive one-word board, becoming the largest number of new pharmaceutical plates so far this year.
market capitalisation of 86.7 billion yuan, up more than 20 times as much as it closed on December 18.
data show that Wante Bio's main business has in-body diagnostic reagents, in-body diagnostic equipment and vaccine research and development, production and sales, core products include HIV diagnostic reagents, viral hepatitis series diagnostic reagents.
the new three-board board, GEM registration system, the new rules of de-listing also came in September this year, Thousand Mountain Retreat (Thousand Yam medicine machine) after the de-listing period was officially delisted.
's share price fell for 29 consecutive sessions as it entered the de-collation period, eventually trading at 0.19 yuan, down 99.75 percent from its all-time high, the biggest drop in A-shares at the time.
It is understood that in the 2015-2016 annual report, Chishan Pharmaceutical Machine has a false reduction in accounts receivable, bad debt preparation, inflated profits and other circumstances, the two-year inflated profit totaled more than 400 million yuan;
as of May, chiyama had nearly 50,000 shareholders.
years, regulators have been constantly improving and establishing a healthy market environment.
last July, the company officially debuted, this year's new three-board board system, GEM registration system reform and other heavy-weight policies, detonated the capital market.
Recently, the Shanghai Stock Exchange and Shenzhen Stock Exchange respectively issued new de-listing rules and supporting system drafts for comments, the new de-listing rules to a large extent absorbed the results of the reform of the board and GEM registration system, mainly from the optimization of the four categories of mandatory de-listing indicators, simplify the de-listing process, strengthen information disclosure and risk warning and other aspects of the current de-listing rules system reform.
the new and old de-marketing standards compared with industry analysis pointed out that the new regulations under the multiple de-marketing standards further reflect the general direction of strict supervision, the number of enterprises de-marketing in the future may gradually increase.
to speed up the clearance of performance stocks, help to reduce invalid supply, and gradually realize the capital market "good currency expulsion of bad money", superimposed on the registration system of the overall promotion, will help improve the overall quality of listed companies.
source: Oriental Fortune Network, announcement of listed companies